Showing 4411-4420 of 5910 results for "".
- Apellis Announces 24-Month Results in Phase 3 Studies Examining Pegcetacoplan in Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-24-month-results-showing-increased-effects-over-time-with-pegcetacoplan-in-phase-3-derby-and-oaks-studies-in-geographic-atrophy-ga/2481045/Apellis Pharmaceuticals announced topline data at 24 months showing increased effects over time with intravitreal pegcetacoplan, an investigational, targeted C3 therapy, in the phase 3 DERBY and OAKS studies in geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
- Glaukos Licenses Iveena’s Investigational Keratoconus Therapyhttps://modernod.com/news/glaukos-licenses-iveenas-investigational-keratoconus-therapy/2481044/Glaukos has acquired an exclusive global license to develop and commercialize iVeena Delivery Systems' investigational pharmacologic treatment for keratoconus, IVMED-80. As part of the agreement, Glaukos paid $10 million upfront and will assume all costs associated with development
- Oculis Announces Publication of Phase 2 Data Showing Eye Drop Drug Candidate Relieves Persistent Ocular Discomfort in Severe Dry Eye Diseasehttps://modernod.com/news/oculis-announces-publication-of-phase-2-data-showing-topical-eye-drop-drug-candidate-ocs-02-relieves-persistent-ocular-discomfort-in-severe-dry-eye-disease/2481042/Oculis announced that the results of the double blinded, multicenter and placebo controlled phase 2 clinical trial assessing the effect of topical licaminlimab (OCS-02) on global ocular discomfort in patients with severe dry eye disease (DED) has been published by the journal C
- Study: Bioengineered Cornea Can Restore Sight to the Blind and Visually Impairedhttps://modernod.com/news/study-bioengineered-cornea-can-restore-sight-to-the-blind-and-visually-impaired/2481039/Researchers and entrepreneurs have developed an implant made of collagen protein from pig’s skin, which resembles the human cornea. In a pilot study, the implant restored vision to 20 people with diseased corneas, most of whom were blind prior to receiving the implant, according to Link&oum
- Show Organizers Announce Reimagined Floor Plan for Vision Expo East 2023https://modernod.com/news/show-organizers-announce-reimagined-floor-plan-for-vision-expo-east-2023/2481037/The Vision Council and RX, co-organizers of Vision Expo, shared plans for a reimagined show floor layout that will debut at Vision Expo East 2023, taking place March 16–19 at the Javits Center in New York City. The new layout will feature all of Vision Expo’s Show Fl
- Visibly Becomes First FDA-Cleared Online Vision Test in the United Stateshttps://modernod.com/news/visibly-becomes-first-fda-cleared-online-vision-test-in-the-united-states/2481033/Visibly, the developer of an at-home digital vision testing platform, announced that it has received 510(k) clearance from the FDA for its Visibly Digital Acuity Product (VDAP). Visibly said it is the first FDA-cleared online visual acuity test on the US market. View Eyew
- Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the Omni Surgical System in Patients with Open Angle Glaucomahttps://modernod.com/news/sight-sciences-announces-long-term-safety-and-effectiveness-data-of-standalone-use-of-the-omni-surgical-system-in-patients-with-open-angle-glaucoma/2481030/Sight Sciences announced 36-month post-surgery follow-up results of the Omni Surgical System. The data demonstrate that the OMNI Surgical System delivers safe, consistent, and durable results in adult patients with open-angle glaucoma (OAG) on a standalone basis, according
- CooperVision MiSight 1 Day Officially Launches in Chinahttps://modernod.com/news/coopervision-misight-1-day-officially-launches-in-china/2481026/CooperVision and EssilorLuxottica have officially launched MiSight 1 day contact lenses in China, marking its availability in the world’s largest country for myopia management. It is the first product of any type that has an indication from the Chinese National Medical Products Adminis
- Clearside Biomedical Enters Into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for Up to $65 Millionhttps://modernod.com/news/clearside-biomedical-enters-into-non-dilutive-financing-agreement-with-healthcare-royalty-partners-for-up-to-65-million/2481020/Clearside Biomedical announced it has entered into an agreement with HealthCare Royalty Partners in a deal worth up to $65 million. Clearside intends to use the proceeds from the agreement to support ongoing clinical development of its pipeline, including CLS-AX (axitini
- Study: Neurolenses Have Significant Impact on Reading Speedhttps://modernod.com/news/neurolenses-have-significant-impact-on-reading-speed/2481017/As has been demonstrated by many studies, contoured prism has historically shown efficacy in relieving symptoms as a therapeutic offering. And new evidence suggests that there is also an opportunity to expand this technology to an even broader population focused on visual performance and producti